Taiwan Radiopharmaceutical Companies and Pipelines
As of October 22, 2026, this table includes 2 Taiwan companies with verified clinical radiopharmaceutical programs: PET Pharm Biotech and Heron Neutron Medical. [1] [2]
The selected [161Tb] PSMA I&T program is Phase 1 for mCRPC; Heron’s F18 FBPA solid-tumor imaging trial is registered as Phase 1/2 and recruiting. [1] [2]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| PET Pharm Biotech Company source | 7762 | [161Tb] PSMA I&T (PPhB-Tb01) | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 1 | 2026-10-22 Stage source [¹⁶¹Tb] PSMA I&T — Phase 1 | — |
| Heron Neutron Medical Company source | 7799 | F18 FBPA (HN-FBPA-001) | PET/CT diagnostic imaging of solid tumors | Phase 1/2; recruiting | 2026-07-09 Stage source RECRUITING | — |
Scope and public-document limits
This is not the total number of Taiwan radiopharmaceutical companies. Other candidates without a verified public stage are excluded; trial results and an approval date for this program remain unfilled.